PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications
Cardiovascular Research · 2023
DOI: 10.1093/cvr/cvad012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Zhifei Xu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, …. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Heart Diseases, Antineoplastic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds.
Abstract (Originalsprache)
Aims
Trastuzumab, the first humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (ERBB2/HER2), is currently used as a first-line treatment for HER2 (+) tumours. However, trastuzumab increases the risk of cardiac complications without affecting myocardial structure, suggesting a distinct mechanism of cardiotoxicity. Methods and results We used medium from trastuzumab-treated human umbilical vein endothelial cells (HUVECs) to treat CCC-HEH-2 cells, the human embryonic cardiac tissue-derived cell lines, and human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to assess the crosstalk between vascular endothelial cells (VECs) and cardiomyocytes. Protein mass spectrometry analysis was used to identify the key factors from VECs that regulate the function of cardiomyocytes. We applied RNA-sequencing to clarify the mechanism, by which PTX3 causes cardiac dysfunction. We used an anti-human/rat HER2 (neu) monoclonal antibody to generate a rat model that was used to evaluate the effects of trastuzumab on cardiac structure and function and the rescue effects of lapatinib on trastuzumab-induced cardiac side effects. Medium from trastuzumab-treated HUVECs apparently impaired the contractility of CCC-HEH-2 cells and iPSC-CMs. PTX3 from VECs caused defective cardiomyocyte contractility and cardiac dysfunction in mice, phenocopying trastuzumab treatment. PTX3 affected calcium homoeostasis in cardiomyocytes, which led to defective contractile properties. EGFR/STAT3 signalling in VECs contributed to the increased expression and release of PTX3. Notably, lapatinib, a dual inhibitor of EGFR/HER2, could rescue the cardiac complications caused by trastuzumab by blocking the release of PTX3.
Conclusion
We identified a distinct mode of cardiotoxicity, wherein the activation of EGFR/STAT3 signalling by trastuzumab in VECs promotes PTX3 excretion, which contributes to the impaired contractility of cardiomyocytes by inhibiting cellular calcium signalling. We confirmed that lapatinib could be a feasible preventive agent against trastuzumab-induced cardiac complications and provided the rationale for the combined application of lapatinib and trastuzumab in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, Zhejiang, PR China.
- Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006,…
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine ; Hangzhou 310003, Zhejiang, PR China.
- Department of Chemotherapy, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, Zhejiang, PR…
- Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, PR China.
- Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou 310018, Zhejiang, PR China.
ORCID-Profile: Peihua Luo
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds
Zitieren
APA
Xu, Z., Gao, Z., Fu, H., Zeng, Y., Jin, Y., Xu, B., Zhang, Y., Pan, Z., Chen, X., Zhang, X., Wang, X., Yan, H., Yang, X., Yang, B., He, Q., & Luo, P. (2023). PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications. Cardiovascular Research. https://doi.org/10.1093/cvr/cvad012
Vancouver
Xu Z, Gao Z, Fu H, Zeng Y, Jin Y, Xu B, et al. PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications. Cardiovascular Research. 2023. doi:10.1093/cvr/cvad012
BibTeX
@article{Xu2023,
author = {Xu, Zhifei and Gao, Zizheng and Fu, Huangxi and Zeng, Yan and Jin, Ying and Xu, Bo and Zhang, Yuanteng and Pan, Zezheng and Chen, Xueqin and Zhang, Xiaochen and Wang, Xiaohong and Yan, Hao and Yang, Xiaochun and Yang, Bo and He, Qiaojun and Luo, Peihua},
title = {PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications},
journal = {Cardiovascular Research},
year = {2023},
doi = {10.1093/cvr/cvad012}
}
EUVIMED